GET THE APP

A Study of the factors associated with the treatment outcome of patients put on Bedaquilline containing treatment regimen for Multi-drug Resistant (MDR) TB
..

Pulmonary & Respiratory Medicine

ISSN: 2161-105X

Open Access

A Study of the factors associated with the treatment outcome of patients put on Bedaquilline containing treatment regimen for Multi-drug Resistant (MDR) TB


3rd World Congress on Advancements in Tuberculosis & Lung Diseases

March 17, 2021 | Webinar

Amit Sharma Co-Authors: DPDK Priya Darshini,Rupak Singla and Neeta Singla

National Institute of Tuberculosis and Respiratory Diseases (NITRD), India

Scientific Tracks Abstracts: J Pulm Respir Med

Abstract :

Bedaquiline (BDQ) has emerged as new hope in the treatment of MDR TB especially in more complicated cases harboring additional drug resistance such as Fluroroquinolone (FQ) resistance. Wiht its unique mechanism of action whereby it inhibits the Mycobacterial ATP synthase, It promises better success rate for a disease with an otherwise dismal prognosis. NITRD, a tertiary Centre for TB and respiratory diseases was one of the initial sites for implementation of BDQ containing regimens. In our study, we tried to assess the treatment outcome of 43 patients of NITRD which were started on BDQ based regime. Our results showed that more than one-third of the patients (69.8%) had favourable outcome as cure or treatment completed. Unfavourable outcome was mostly associated with increasing age, extensive involvement of Lung parenchyma, addictions (alcoholism, smoking) and concurret Diabetes. Culture conversion time, type of TB, whether Pulmonary or Extra-pulmonary, type of resistance, Second line injectables (SLI) and/or Fluoroquinolone (FQ) and Sputum smear grading were not found to have any association with the treatment outcome of patients on Bedaquiline containing regimen. Our results are encouraging since a good outcome was achieved in patients with more extensive resistace pattern. BDQ has emerged has a potent weapon in the arsenall of anti-tubercular drugs and is now classified in the group A drugs for treatment of MDR TB. Its use is now finding application in national as well as international TB Elimination programmes all around the globe.

Biography :

Amit Sharma has done his MBBS from Maulana Azad Medical College and MD in Pulmonary Medicine from Vallabhbhai Patel Chest Institute both under University of Delhi. He is working in NITRD from 2010 as a Chest Physician and has almost 19 years of experience in managing Tuberculosis and Respitary Diseases. He has been a Supervisor and Co-supervisor in the dissertation of more than 10 PG Residents and is the first or second author in 4 international and 1 national publication.

Google Scholar citation report
Citations: 1690

Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report

Pulmonary & Respiratory Medicine peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward